Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Haber

Showing results (151-160 of 186) with videos related to

Pageof 19
Sort By:
Cell Reports|April 14, 2021
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPGAnahid Ehteda, Sandy Simon, Laura Franshaw, et al.
Oncotarget|October 21, 2016
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugsPei Y Liu, Nicholas Sokolowski, Su T Guo, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2025
The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated responseRuby Pandher, Chengyuan Xue, Laura D Gamble, et al.
Oncogene|March 4, 2021
A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastomaBelamy B Cheung, Ane Kleynhans, Rituparna Mittra, et al.
Science Translational Medicine|May 17, 2023
Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemiaErnest Moles, Christopher B Howard, Pie Huda, et al.
International Journal of Cancer|November 8, 2022
Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastomaJanith A Seneviratne, Daniel R Carter, Rituparna Mittra, et al.
Nature Communications|July 27, 2019
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastomaMatthew Wong, Yuting Sun, Zhichao Xi, et al.
Research Square|August 6, 2025
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivityJohn Maris, Isabel Soria-Bretones, Matias Casás-Selves, et al.
Nature Communications|May 19, 2026
Precision-guided therapy in H3K27-altered diffuse midline gliomaCampbell J L McKay, Chelsea Mayoh, Phoebe Power, et al.
Cancer Research|September 11, 2019
Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding InterfaceJessica Koach, Jessica K Holien, Hassina Massudi, et al.
Pageof 19

Showing results (151-160 of 186) with videos related to

Sort By:
Pageof 19
Cell Reports|April 14, 2021
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPGAnahid Ehteda, Sandy Simon, Laura Franshaw, et al.
Oncotarget|October 21, 2016
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugsPei Y Liu, Nicholas Sokolowski, Su T Guo, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2025
The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated responseRuby Pandher, Chengyuan Xue, Laura D Gamble, et al.
Oncogene|March 4, 2021
A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastomaBelamy B Cheung, Ane Kleynhans, Rituparna Mittra, et al.
Science Translational Medicine|May 17, 2023
Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemiaErnest Moles, Christopher B Howard, Pie Huda, et al.
International Journal of Cancer|November 8, 2022
Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastomaJanith A Seneviratne, Daniel R Carter, Rituparna Mittra, et al.
Nature Communications|July 27, 2019
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastomaMatthew Wong, Yuting Sun, Zhichao Xi, et al.
Research Square|August 6, 2025
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivityJohn Maris, Isabel Soria-Bretones, Matias Casás-Selves, et al.
Nature Communications|May 19, 2026
Precision-guided therapy in H3K27-altered diffuse midline gliomaCampbell J L McKay, Chelsea Mayoh, Phoebe Power, et al.
Cancer Research|September 11, 2019
Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding InterfaceJessica Koach, Jessica K Holien, Hassina Massudi, et al.
Pageof 19